TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
First Claim
1. A composition comprising at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more synthetic target peptides, each of which is at least or about 8, 9, 10, 11, 12, 13, 14, or 15 amino acids long, comprising:
- a first peptide comprising a sequence selected from the group consisting of SEQ ID NO;
398, SEQ ID NO;
2000, SEQ ID NO;
2001, and SEQ ID NO;
2002; and
/ora second peptide comprising a sequence selected from the group consisting of SEQ ID NO;
418, SEQ ID NO;
2062, and SEQ ID NO;
2063; and
/oran optional third peptide comprising a sequence selected from the group consisting of SEQ ID NO;
427;
SEQ ID NO;
2078, SEQ ID NO;
2079, SEQ ID NO;
2080, SEQ ID NO;
2081, SEQ ID NO;
2082, SEQ ID NO;
2083, and SEQ ID NO;
2084; and
/oran optional fourth peptide selected from the group consisting of GLLGpSPVRA (SEQ ID NO;
396; and
SEQ ID NO;
1996; and
/oran optional fifth peptide from the group consisting of VMIGsPKKV (SEQ ID NO;
426) and (SEQ ID NO;
2077);
wherein said composition has the ability to stimulate an T cell mediated immune response to said first, second and/or third peptides; and
optionally wherein the composition is capable of eliciting a memory T cell response to said first, second and/or third peptides.
7 Assignments
0 Petitions
Accused Products
Abstract
A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.
-
Citations
51 Claims
-
1. A composition comprising at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more synthetic target peptides, each of which is at least or about 8, 9, 10, 11, 12, 13, 14, or 15 amino acids long, comprising:
-
a first peptide comprising a sequence selected from the group consisting of SEQ ID NO;
398, SEQ ID NO;
2000, SEQ ID NO;
2001, and SEQ ID NO;
2002; and
/ora second peptide comprising a sequence selected from the group consisting of SEQ ID NO;
418, SEQ ID NO;
2062, and SEQ ID NO;
2063; and
/oran optional third peptide comprising a sequence selected from the group consisting of SEQ ID NO;
427;
SEQ ID NO;
2078, SEQ ID NO;
2079, SEQ ID NO;
2080, SEQ ID NO;
2081, SEQ ID NO;
2082, SEQ ID NO;
2083, and SEQ ID NO;
2084; and
/oran optional fourth peptide selected from the group consisting of GLLGpSPVRA (SEQ ID NO;
396; and
SEQ ID NO;
1996; and
/oran optional fifth peptide from the group consisting of VMIGsPKKV (SEQ ID NO;
426) and (SEQ ID NO;
2077);wherein said composition has the ability to stimulate an T cell mediated immune response to said first, second and/or third peptides; and
optionally wherein the composition is capable of eliciting a memory T cell response to said first, second and/or third peptides. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34, 35, 36, 37, 39, 40, 44)
-
-
28. An antibody or antibody-like molecule that specifically binds to both a first complex of MHC class I molecule and a peptide represented by SEQ ID NO:
- 2080 and a second complex of MHC class I molecule and a peptide represented by SEQ ID NO;
427;
wherein the antibody or antibody-like molecule does not bind the same complexes containing an unphosphorylated version of SEQ ID NO;
2080 or SEQ ID NO;
427. - View Dependent Claims (29, 30, 31, 32, 33, 38)
- 2080 and a second complex of MHC class I molecule and a peptide represented by SEQ ID NO;
-
41. A method of determining the prognosis of a cancer patient comprising:
-
(a) administering a target peptide associated with the patient'"'"'s cancer to the cancer patient; (b) determining whether the target peptide is capable of inducing a target peptide-specific memory T cell response in the cancer patient; and (c) determining that the cancer patient has a better prognosis if the cancer patient mounts a memory T cell response to said target peptide than if the cancer patient did not mount a memory T cell response to said target peptide.
-
- 42. A kit comprising at least one target peptide composition comprising at least one target peptide and a cytokine and/or an adjuvant.
Specification